Day: March 7, 2024

WILMINGTON, Del., March 07, 2024 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (OTCQB: ACFN), a provider of remote monitoring and control solutions for backup power generators, gas pipelines, air compressors and other mission critical assets, announced results for its fourth quarter (Q4’23) and full-year periods ended December 31, 2023. Acorn achieved profitability in Q4’23 and for the full year 2023 on revenue growth of 22% and 15%, respectively. The company will hold an investor call today at 11am ET (see call details below). Summary Financial Results (1)                       ($ in thousands) Q4’23 Q4’22 Change     2023     2022   ChangeMonitoring revenue $ 1,090   $ 998   +9.2 %   $ 4,262   $ 3,912   +8.9 %Hardware revenue $ 1,160   $ 847   +37.0 %   $ 3,797   $ 3,088   +23.0 %Total revenue $ 2,250   $ 1,845   +22.0 %   $ 8,059   $ 7,000   +15.1 %Gross...

TORONTO, March 07, 2024 (GLOBE NEWSWIRE) — Stack Capital Group Inc., (“Stack Capital” or the “Company”) (TSX: STCK and STCK.WT) today announced its financial results for the year ended December 31, 2023. Stack Capital reports all amounts in Canadian Dollars unless otherwise stated. Company Commentary:As at December 31, 2023, Book Value per Share (BVpS) of the Company was $10.91, compared with $11.30 as at September 30, 2023.During Q4, currency fluctuations resulted in a $0.19 drag to BVpS. As of today, the US dollar has recovered, thereby reversing the $0.19 decrease in BVpS.Stack Capital increased its exposure to Locus Robotics through a share-swap transaction issuing 273,501 Stack Capital common shares, at $11.30 per share, which closed on March 4, 2024.The Company’s cash position as at December 31, 2023, was $25.1...

Strong performance while investing in the business MISSISSAUGA, Ontario, March 07, 2024 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) reports the Q4 2023 and full year 2023 financial and operational results of KPT and Kruger Products Inc. (Kruger Products). Kruger Products is Canada’s leading manufacturer of quality tissue products for the Consumer market (Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and BonterraTM) and the Away-From-Home (AFH) market and continues to grow in the U.S. Consumer tissue business with the White Cloud® brand and premium private label products. KPT currently holds a 12.9% interest in Kruger Products. Kruger Products Q4 2023 Business and Financial HighlightsRevenue was $482.3 million in Q4 2023 compared to $458.1 million in Q4 2022, an increase of $24.2 million or 5.3%. Adjusted...

PDUFA target action date is March 16, 2024, for the Company’s sNDA. If approved, the Company is prepared for launch of XHANCE for treatment of patients diagnosed with chronic sinusitis Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal polyps indication and there is no FDA-approved medication for these patients Company reports fourth quarter and full year 2023 XHANCE net revenue of $19.9 million and $71.0 million Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., March 07, 2024 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2023, and provided recent operational highlights. “Our...

• Dose escalation in FHD-286 combination study in AML continues to progress; clinical data anticipated in the second half of 2024 • FHD-909, a first-in-class BRM selective inhibitor, selected for clinical development by partner Lilly; preclinical data to be presented at AACR with IND planned for the second quarter, primary target patient population in non-small cell lung cancer • Selective CBP and EP300 degrader preclinical data to be presented at AACR; IND-enabling studies for CBP degrader program planned to begin by end of 2024 • Foghorn anticipates at least six new INDs targeting significant oncology patient populations over the next four years, reflecting the continued productivity of its precision medicine platform • Cash, cash equivalents, and marketable securities of $234.1 million, as of December 31, 2023, provide cash runway into...

– Announced positive topline efficacy and safety data from the Phase 2 DAVIO 2 trial of EYP-1901 in wet AMD achieving all primary and secondary endpoints; initiation of the first Phase 3 clinical trial expected in 2H 2024 – – Dosed first patient in Phase 2 VERONA clinical trial of EYP-1901 in DME; topline data expected in 1Q 2025 – – Phase 2 PAVIA clinical trial topline data of EYP-1901 in moderately severe-to-severe NPDR anticipated in 2Q 2024 – – Announced appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer –  – $331M of cash and investments on December 31, 2023, with cash runway through topline data of Phase 3 trials for EYP-1901 for wet AMD in 2026 –  – Management to host a conference call and webcast today at 8:30 a.m. ET – WATERTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ:...

CHICAGO, March 07, 2024 (GLOBE NEWSWIRE) — Methode Electronics, Inc. (NYSE: MEI), a leading global supplier of custom-engineered solutions for user interface, LED lighting and power distribution applications, today announced financial results for the third quarter of fiscal 2024 ended January 27, 2024. Fiscal Third Quarter 2024 HighlightsNet sales were $259.5 million Electric and hybrid vehicle applications were 19 percent of net sales Net loss was $11.6 million, or $0.33 per diluted share Free cash flow was $12.2 million Company purchased 130,592 shares of its common stock for $3.0 million Forward-looking guidance suspendedManagement CommentsPresident and Chief Executive Officer Avi Avula said, “Our sales in the quarter were impacted by auto program roll-offs and persistent demand weakness in the e-bike and data center markets....

Q4 Revenues of $28.2 million Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) Q4 operating income of $0.3 million, adjusted operating income of $3.3 million Strong operating cash flow enabled 2023 debt reduction of $10.5 million and a significant decrease in net leverageHOLLISTON, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023. Jim Green, Chairman and CEO said, “Our fourth quarter revenue was down a modest 1% compared to the prior year quarter in a challenging APAC marketplace. Revenue included a net reduction of approximately $0.9 million of remaining discontinued products from prior year. We saw significant gross margin expansion and continued our relentless focus on enhancing...